<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62127">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01974336</url>
  </required_header>
  <id_info>
    <org_study_id>UDCA-PNAC-SBS</org_study_id>
    <nct_id>NCT01974336</nct_id>
  </id_info>
  <brief_title>The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients</brief_title>
  <official_title>The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Parenteral Nutrition-associated Cholestasis in Short Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinling Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jinling Hospital, China</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of UDCA in treating the parenteral nutrition-associated cholestasis(PNAC) has
      been identified by  some studies in children without short bowel syndrome(SBS).Most of the
      adults who suffering PNAC have SBS. it limits the potential function of UDCA  because of the
      lack of SBS patients and malabsorption of UDCA.Therefore, we design this clinical trial in
      our center of SBS to approach the preventative and therapeutical effect of UDCA to PNAC in
      adults with short bowel syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The biochemical indicator of patients' liver function during oral UDCA or placebo</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>detect the biochemical indicator of patients' liver function(Serum bilirubin, GGT Valley, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase) during oral UDCA or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the changs of composition of serum bile acid  after oral UDCA or placebo</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>we test the composition of serum bile acid at the beginning,2 months,4 months(the end) of the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changs of the level of fibroblast growth factor 19(FGF19) in the serum</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>we test the level of FGF19 in the serum at the beginning,2 months,4months(the end) of the trail.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>UDCA+placebo group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15-30mg/kg/d UDCA for 2 months + placebo for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo+UDCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo for 2 months+15-30mg/kg/d UDCA for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>placebo for 2 months + placebo for 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ursodeoxycholic acid</intervention_name>
    <arm_group_label>UDCA+placebo group</arm_group_label>
    <arm_group_label>placebo+UDCA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with short bowel syndrome supported by total parenteral nutrition.

          -  Patients have intestine more than 50cm.

          -  Requirements of informed consent and assent of participant, parent or legal guardian
             as applicable

          -  Consciousness and ability to cooperate.

        Exclusion Criteria:

          -  Patients have obstruction of biliary tract, infection, autoimmune disease, cancer

          -  Patients have intestine less than 50cm

          -  A clinically significant laboratory abnormality or a history of significant cardiac,
             pulmonary, hepatic, or renal disease

          -  Female with positive pregnancy

          -  Allergy to ursodeoxycholic acid
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wencheng Kong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wengcheng Kong, MD</last_name>
    <phone>15850722032</phone>
    <email>wenchengkong@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yousheng Li</last_name>
    <phone>8602580860137</phone>
    <email>liys@medmail.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>200002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wencheng Kong, MD</last_name>
      <phone>15850722032</phone>
      <email>wenchengkong@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>jian wang</last_name>
      <email>jian.wang@foxmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wencheng Kong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>jian wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danhua Yao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>October 26, 2013</lastchanged_date>
  <firstreceived_date>October 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jinling Hospital, China</investigator_affiliation>
    <investigator_full_name>Kong Wencheng</investigator_full_name>
    <investigator_title>Senior Resident</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
